Results from Phase III Pooled EINSTEIN Studies Reaffirm Bayer's Xarelto® as an Effective Single-Drug Solution for Venous

Results from Phase III Pooled EINSTEIN Studies Reaffirm Bayer's Xarelto® as 
an Effective Single-Drug Solution for Venous Thromboembolism 
Not intended for U.S. and UK Media 
Treatment and prevention of venous blood clots: 


    --  Blood clots obstructing blood flow in deep veins or in the
        lungs kill one person every 37 seconds in the Western World
    --  Pooled data of over 8,000 patients reaffirm the improved
        benefit-risk profile of Xarelto as an effective single-drug
        solution compared with the traditional dual-drug therapy
    --  Xarelto associated with 46% less major bleeding events,
        including fatal bleeding compared to standard dual-drug
        therapy, whilst having similar overall incidence rates for the
        principal safety outcome of major or non-major clinically
        relevant bleeding
    --  Additionally, a sub-analysis of the EINSTEIN DVT study
        published in the journal Thrombosis and Haemostasis confirms
        that Xarelto improves treatment satisfaction compared with
        traditional dual-drug therapy and indicates better adherence
        and persistence in long-term prevention of recurrent venous
        blood clots compared with vitamin K antagonists (VKAs)
    --  Bayer's 'Responsible Use Programme' for physicians and patients
        supports best practice, helping to achieve improved clinical
        outcomes with 'Xarelto'

BERLIN, Sept. 20, 2013 /CNW/ - Data from the Phase III EINSTEIN clinical trial 
programme published today in the Thrombosis Journal underline that single-drug 
therapy with Bayer HealthCare's novel oral anticoagulant Xarelto(®) 
(rivaroxaban) is effective in both the treatment and subsequent prevention of 
recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), with an 
overall comparable safety to the traditional dual-drug therapy.

In addition, compared to the traditional dual-drug approach of injectable low 
molecular weight heparin (LMWH) followed by a vitamin K antagonist (VKA), 
Xarelto significantly reduced the rate of major bleeding events by 46 per 
cent, including the risk of fatal bleeding, whilst offering an improved 
benefit-risk profile regardless of patient age, frailty, gender, weight or 
renal function.

To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/62405-pooled-einstein-study-bayer-xarelto

"Today's publication of these impressive data further highlights the potential 
of this drug to change current clinical practice in both the treatment of 
initial acute DVT and PE, as well as the prevention of recurrent DVT and PE," 
said Dr Alexander T. Cohen, King's College Hospital, London, and member of the 
Steering Committee of the EINSTEIN studies. "The unique single-drug therapy of 
rivaroxaban has the potential to not only improve clinical outcomes, but also 
reduce the overall burden of anticoagulation therapy by providing continuous 
patient management from hospital to home while avoiding the need for 
injections or routine coagulation monitoring."

Additionally, a sub-analysis of the EINSTEIN DVT study recently pre-published 
online in the journal Thrombosis and Haemostasis confirms that Xarelto 
improves treatment satisfaction compared with traditional dual-drug therapy. 
The data also indicate improved adherence and persistence with Xarelto in 
long-term prevention of recurrent venous blood clots compared with VKAs such 
as warfarin. These findings complement an analysis of patient-reported 
satisfaction in the EINSTEIN PE study, and indicate an important adherence and 
persistence benefit with Xarelto in both acute treatment and long-term 
prevention regardless of the type of venous blood clot experienced.

"These analyses add to the large amount of clinical data and real-life 
experience supporting Xarelto in the management of both venous and arterial 
blood clots, providing further reassurance regarding the clinical use of 
Xarelto across a broad range of clinical settings," said Dr. Kemal Malik, 
Member of the Bayer HealthCare Executive Committee and Head of Global 
Development.

Xarelto is approved for five indications across seven distinct areas of use, 
consistently protecting patients across more venous and arterial 
thromboembolic (VAT) conditions than any other novel oral anticoagulant.

About The EINSTEIN Clinical Trial Programme and Pooled Analysis

The pivotal EINSTEIN Clinical Trial Programme comprises three Phase III 
studies evaluating rivaroxaban alone versus the dual-drug regimen of low 
molecular weight heparin (LMWH) and a vitamin K antagonist (VKA) in the 
treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the 
prevention of recurrent DVT and PE.

In the pooled analysis of over 8,000 patients, rivaroxaban showed 
non-inferiority versus the LMWH enoxaparin and VKA in terms of efficacy (HR 
0.89 (95% CI 0.66-1.19), p=<0.0001) and similar overall incidence rates to 
enoxaparin and VKA for the principal safety outcome of major or non-major 
clinically relevant bleeding (HR 0.93 (95% CI 0.81-1.06), p=0.272). 
Importantly, rivaroxaban showed a significant reduction in major bleeding (HR 
0.54 (95% CI 0.37-0.79), p=0.002) over traditional dual-drug therapy. Overall, 
the principal safety results were consistent regardless of the patient's age, 
frailty, weight, gender and renal function. Results from the pooled analysis 
were previously presented at the 54(th) American Society of Hematology (ASH) 
Annual Meeting in Atlanta in December 2012.

Xarelto is approved as the single-drug solution for the treatment of DVT and 
PE as well as for the prevention of recurrent DVT and PE in adults in a number 
of countries worldwide including Europe and the U.S.

About Venous Arterial Thromboembolism (VAT) 
Thrombosis is the formation of a blood clot inside a blood vessel, blocking a 
vein (venous thrombosis) or artery (arterial thrombosis). Venous Arterial 
Thromboembolism (VAT) is caused when some or all of a clot detaches and is 
moved within the blood stream until it obstructs a smaller vessel. This can 
result in damage to vital organs, because the tissue beyond the blockage no 
longer receives nutrients and oxygen.

VAT is responsible for a number of serious and life threatening conditions:

•Venous Thromboembolism (VTE) occurs when part of a clot formed in a deep 
vein, for example in the leg (known as deep vein thrombosis, or DVT), is 
carried to the lung, via the heart, preventing the uptake of oxygen. This is 
known as a pulmonary embolism (PE), an event which can be rapidly fatal. Blood 
clots that obstruct blood flow in deep veins or in the lungs kill one person 
every 37 seconds in the Western World

•Arterial Thromboembolism occurs when oxygenated blood flow from the heart 
to another part of the body (via an artery) is interrupted by a blood clot. If 
this occurs in a vessel supplying blood to the brain, it can lead to a stroke, 
an event that can be severely debilitating or fatal. If it occurs in a 
coronary artery, it can lead to acute coronary syndrome (ACS), a complication 
of coronary heart disease which includes conditions such as myocardial 
infarction and unstable angina

VAT is responsible for significant morbidity and mortality, and requires 
active or preventative treatment to avoid potentially serious or fatal patient 
outcomes.

To learn more about VAT, please visit http://www.VATspace.com

About Xarelto(®)(Rivaroxaban)

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is 
marketed under the brand name Xarelto(®). Xarelto is approved for five 
indications across seven distinct areas of use, consistently protecting 
patients across more venous and arterial thromboembolic (VAT) conditions than 
any other novel OAC:

•The prevention of stroke and systemic embolism in adult patients with 
non-valvular atrial fibrillation (AF) with one or more risk factors

•The treatment of deep vein thrombosis (DVT) in adults

•The treatment of pulmonary embolism (PE) in adults

•The prevention of recurrent DVT and PE in adults

•The prevention of venous thromboembolism (VTE) in adult patients 
undergoing elective hip replacement surgery

•The prevention of venous thromboembolism (VTE) in adult patients 
undergoing elective knee replacement surgery

•The prevention of atherothrombotic events (cardiovascular death, 
myocardial infarction or stroke) after an Acute Coronary Syndrome in adult 
patients with elevated cardiac biomarkers when co-administered with 
acetylsalicylic acid (ASA) alone or with ASA plus a thienopyridine 
(clopidogrel or ticlopidine)

Whilst licences may differ from country to country, across all indications 
Xarelto is approved in more than 120 countries.

Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed 
with Janssen Research & Development, LLC. Xarelto is marketed outside the U.S. 
by Bayer HealthCare and in the U.S. by Janssen Pharmaceuticals, Inc. (a 
Johnson & Johnson Company).

Anticoagulant medicines are potent therapies used to prevent or treat serious 
illnesses and potentially life-threatening conditions. Before initiating 
therapy with anticoagulant medicines, physicians should carefully assess the 
benefit and risk for the individual patient.

Responsible use of Xarelto is a very high priority for Bayer, and the company 
has developed a Prescribers Guide for physicians and a Xarelto Patient Card 
for patients to support best practice.

To learn more, please visit https://prescribe.xarelto.com
To learn more about thrombosis, please visit http://www.thrombosisadviser.com
To learn more about Xarelto, please visit http://www.xarelto.com

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of 
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup 
of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the 
world's leading, innovative companies in the healthcare and medical products 
industry and is based in Leverkusen, Germany. The company combines the global 
activities of the Animal Health, Consumer Care, Medical Care and 
Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, 
manufacture and market products that will improve human and animal health 
worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 
31, 2012) and is represented in more than 100 countries. More information at 
http://www.healthcare.bayer.com.

Our online press service is just a click away: press.healthcare.bayer.com

Find more information at http://www.bayerpharma.com.
sp  (2013-0359E)

Forward-Looking Statements
This release may contain forward-looking statements based on current 
assumptions and forecasts made by Bayer Group or subgroup management. Various 
known and unknown risks, uncertainties and other factors could lead to 
material differences between the actual future results, financial situation, 
development or performance of the company and the estimates given here. These 
factors include those discussed in Bayer's public reports which are available 
on the Bayer website at http://www.bayer.com. The company assumes no liability 
whatsoever to update these forward-looking statements or to conform them to 
future events or developments.

Video: http://www.multivu.com/mnr/62405-pooled-einstein-study-bayer-xarelto



SOURCE  Bayer HealthCare 
Astrid Kranz, Tel. +49-30-468-12057, E-Mail:astrid.kranz@bayer.com; 
Stephanie Prate, Tel +49-30-468-196053, E-Mail:stephanie.prate@bayer.com 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/September2013/20/c9147.html 
CO: Bayer HealthCare
NI: HEA  
-0- Sep/20/2013 13:58 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.